ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2020
Prophylactic efficacy of 5-HT
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- Effects on hippocampal activity following novel 5-HT4 receptor agonism in unmedicated patients with depression: the RESTAND study.Translational psychiatry · 2026Trial
- Pro-cognitive effects of 5-HT4 receptor agonism in individuals with remitted depression.Psychological medicine · 2026Trial
- Activation of 5-HT4 receptors reverses stress-induced dopamine system dysregulation.Neuropharmacology · 2026Article
- Prucalopride, a serotonin type 4 receptor agonist, induces fast anxiolytic/antidepressant effects and concomitant changes in the gut microbiota.NPJ biofilms and microbiomes · 2026Article
- Novel, small molecules targeting the 5-HTbioRxiv : the preprint server for biology · 2025Article
- Effects on hippocampal activity following 5-HT4 receptor agonism in unmedicated patients with depression: the RESTAND study.medRxiv : the preprint server for health sciences · 2025Article
- Combinatorial targeting of NMDARs and 5-HTAlzheimer's research & therapy · 2025Article
- Chronic, combinatorial targeting of NMDARs and 5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Dopamine D2 receptor agonists prevent impairment of maternal care in lipopolysaccharide-induced postpartum depression model mice.The Journal of veterinary medical science · 2025Article
- GluN2B on Adult-Born Granule Cells Modulates (R,S)-Ketamine's Rapid-Acting Effects in Mice.The international journal of neuropsychopharmacology · 2024Article
- Association between a selective 5-HTThe British journal of psychiatry : the journal of mental science · 2024Article
- Stress Hormone Dynamics Are Coupled to Brain Serotonin 4 Receptor Availability in Unmedicated Patients With Major Depressive Disorder: A NeuroPharm Study.The international journal of neuropsychopharmacology · 2023Article
- Serotonin 4 Receptor Brain Binding in Major Depressive Disorder and Association With Memory Dysfunction.JAMA psychiatry · 2023Article
- Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding. A NeuroPharm-1 study.Translational psychiatry · 2022Article
- Novel drug developmental strategies for treatment-resistant depression.British journal of pharmacology · 2022Review
- The Effect of the 5-HTFrontiers in psychiatry · 2022Article
- The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study.Frontiers in endocrinology · 2022Article
- Déjà-vu? Neural and behavioural effects of the 5-HTTranslational psychiatry · 2021Article
- Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior.Biological psychiatry · 2021Article
- Fluoroethylnormemantine, A Novel Derivative of Memantine, Facilitates Extinction Learning Without Sensorimotor Deficits.The international journal of neuropsychopharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Enhancing stress resilience could protect against stress-induced psychiatric disorders in at-risk populations. We and others have previously reported that (R,S)-ketamine acts as a prophylactic against stress when administered 1 week before stress. While we have shown that the selective 5-hydroxytryptamine (5-HT) (serotonin) reuptake inhibitor (SSRI) fluoxetine (Flx) is ineffective as a prophylactic, we hypothesized that other serotonergic compounds such as serotonin 4 receptor (5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.